ライフサイエンスコーパス: 2-deoxy-D-glucose

1 ecific substrates (L-glucose, D-mannose, and 2-deoxy-D-glucose).

2 only 28% of saline controls' after systemic 2-deoxy-D-glucose.

3 ular ATP by the addition of sodium azide and 2-deoxy-D-glucose.

4 food, or glucoprivation induced by systemic 2-deoxy-D-glucose.

5 the abundance of glucose and the removal of 2-deoxy-D-glucose.

6 ed with dynamic PET imaging of [(18)F]fluoro-2-deoxy-D-glucose.

7 eripheral tissues were measured using [(3)H]-2-deoxy-D-glucose.

8 the presence of the glycosylation inhibitor 2-deoxy-d-glucose.

9 positron emission tomography using 18-fluoro-2-deoxy-d-glucose.

10 Myotube 2-deoxy-D-glucose (0.05 mM) uptake was unaffected by cha

11 posure to 2, 4-dinitrophenol (50 microM) and 2-deoxy-D-glucose (10 mM) stimulated outward currents ca

12 ed by labelling cells with 2'-[(18)F]-fluoro-2'-deoxy-D-glucose ((18)F-FDG).

13 ulticenter clinical trial using (18)F-fluoro-2-deoxy-d-glucose ((18)F-FDG), (18)F-fluoromisonidazole

14 The PET tracers 2-(18)F-fluoro-2-deoxy-d-glucose ((18)F-FDG), 3'-deoxy-3'-(18)F-fluorot

15 ectroscopic imaging (MRSI) and [(18)F]fluoro-2-deoxy-D-glucose ((18)FDG) positron emission tomography

16 28)-A20FMDV2 was superior to 2-[(18)F]fluoro-2-deoxy-d-glucose ([(18)F]FDG) in imaging the BxPC-3 tum

17 2-[(18)F]fluoro-2-deoxy-D-glucose ([(18)F]FDG), which is sequestered in

18 to measure regional uptake of (18F)-2-fluoro-2-deoxy-D-glucose (18FDG) following its intravenous inje

19 ience, however, with PET using 2-[18F]fluoro-2-deoxy-D-glucose (18FDG) in carcinoid is very limited.

20 tio (DUR), a widely used index of 18F-fluoro-2-deoxy-D-glucose (18FDG) metabolism in a variety of tum

21 The energy antimetabolites 2-deoxy-D-glucose (2-DG) and Na-2-mercaptoacetate (MA) b

22 The combination of 2-deoxy-D-glucose (2-DG) and UA-4 induced cell cycle arr

23 It is well known that 2-Deoxy-d-glucose (2-DG) blocks intracellular utilizatio

24 2-deoxy-D-glucose (2-DG) has been shown to induce increa

25 ategy in vivo using the glycolytic inhibitor 2-deoxy-D-glucose (2-DG) in combination with Adriamycin

26 The glucose analog 2-deoxy-D-glucose (2-DG) mimics CR effects in several an

27 effects of acute metabolic stress induced by 2-deoxy-D-glucose (2-DG) on pituitary-adrenal axis activ

28 Insulin-stimulated (17 nmol/l) 2-deoxy-D-glucose (2-DG) uptake was inhibited 31% in adi

29 The glycolytic inhibitor 2-deoxy-d-glucose (2-DG) was used to test the efficacy o

30 ria-targeted drugs (MTD) in combination with 2-deoxy-d-glucose (2-DG), a compound that inhibits glyco

31 2-Deoxy-d-glucose (2-DG), a synthetic glucose analogue t

32 We studied the effects of inhibitors (2-deoxy-D-glucose (2-DG), iodoacetate (IAA)), intermedia

33 enge, intraperitoneal-administered 350 mg/kg 2-deoxy-D-glucose (2-DG), on food intake were measured i

34 atory blood glucose responses to insulin and 2-deoxy-d-glucose (2-DG).

35 ion therapy using periocular carboplatin and 2-deoxy-d-glucose (2-DG).

36 the planarians to D-glucose (1 microM) or to 2-deoxy-D-glucose (2-DG, 1 microM), but not to L-glucose

37 riment 2 tested the effects of the compound, 2-deoxy-D-glucose (2-DG, 200 and 400 mg/kg), which block

38 -(7-nitrobenz-2-oxa-1, 3-diazol-4-yl) amino]-2-deoxy-D-glucose (2-NBDG) reports on glucose uptake and

39 2-Deoxy-D-glucose (200 and 400 mg/kg) produced selective

40 be mimicked by dietary supplementation with 2-deoxy-D-glucose (2DG) a non-metabolizable glucose anal

41 uced by the anti-metabolic glucose analogue, 2-deoxy-d-glucose (2DG) across a 4 h time course.

42 The current work tests the hypothesis that 2-deoxy-d-glucose (2DG) combined with cisplatin [cis-dia

43 bition of glycolysis with the glucose analog 2-deoxy-D-glucose (2DG) during the period of exposure to

44 ng glycolysis using the glycolytic inhibitor 2-deoxy-D-glucose (2DG) in experimental models of seizur

45 ated the effects of the glycolytic inhibitor 2-deoxy-D-glucose (2DG) in the rat kindling model of tem

46 2-Deoxy-d-glucose (2DG) is a glucose analogue that inhib

47 Because 2-deoxy-D-glucose (2DG) is a potent inhibitor of glucose

48 eatment with low doses of the glucose analog 2-deoxy-d-glucose (2DG) on ADPKD progression in ortholog

49 tory challenges as glucoprivation induced by 2-deoxy-D-glucose (2DG) or food deprivation in rodents.

50 Systemic 2-deoxy-d-glucose (2DG) produces pronounced torpor-like

51 enuated stimulation of AgRP mRNA and AMPK by 2-deoxy-d-glucose (2DG), implicating that brain GLUT2 ma

52 p.) injection of the glucose antimetabolite, 2-deoxy-D-glucose (2DG), or saline.

53 or of glycolysis and N-linked glycosylation, 2-deoxy-D-glucose (2DG), potently inhibited surface expr

54 ord (T2-T4) and subsequently tested rats for 2-deoxy-D-glucose (2DG)-induced feeding and blood glucos

55 experiment examined the effects of repeated 2-deoxy-D-glucose (2DG)-induced glucoprivation on subseq

56 In addition, 2-deoxy-D-glucose (2DG)-induced hyperphagia, central Ang

57 rain samples were collected from control and 2-deoxy-d-glucose (2DG)-injected rats for Western blot a

58 SPN) activated by glucoprivation, induced by 2-deoxy-D-glucose (2DG).

59 cylimidazole (NDI) with glycolytic inhibitor 2-deoxy-d-glucose (2DG).

60 2-deoxy-D-glucose (2DG; 200 mg/kg) was used to induce gl

61 cted bilaterally into A1/C1 and responses to 2-deoxy-D-glucose (2DG; 200 mg/kg)-induced glucoprivatio

62 urons by the antimetabolic glucose analogue, 2-deoxy-D-glucose (2DG; 50, 100, 200 or 400 mg/kg, s.c.)

63 hway is also inhibited by treatments such as 2-deoxy-D-glucose (2dGlc) or glucose deprivation that in

64 essed at the yeast cell membrane and restore 2-deoxy-d-glucose, 3-O-methylglucose, and d-glucose tran

65 values for [3H]cytochalasin B binding were: 2-deoxy-D-glucose (4.5 mM) > or = D-glucose (7 mM) > man

66 2-Deoxy-D-glucose (500 mg/kg, i.p.)-induced hyperphagia

67 ntake under deprivation (24 h), glucoprivic (2-deoxy-D-glucose, 500 mg/kg, i.p.) or palatable (10% su

68 , Pi, and PPi and only modestly depressed by 2-deoxy-D-glucose 6-phosphate, a poor substrate for Glc-

69 retion caused by the central vagal stimulant 2-deoxy-D-glucose (75 mg kg(-1)), whereas bethanechol-st

70 e wall (electron component) for 2-18F-fluoro-2-deoxy-D-glucose, 99mTc-diethylenetriaminepentaacetic a

71 ts that received isotonic saline or systemic 2-deoxy-d-glucose (a glucose antimetabolite).

72 imal semiquantitative measure of [18F]fluoro-2-deoxy-D-glucose accumulation in sarcoma and standardiz

73 Using 2-deoxy-d-glucose, an inhibitor of glucose uptake, and c

74 ns but did not alter the uptake rate of this 2-deoxy-D-glucose analog in astrocytes.

75 atment increased the uptake of a fluorescent 2-deoxy-D-glucose analog in neurons but did not alter th

76 etformin unexpectedly decreased transport of 2-deoxy-d-glucose and 3-O-methyl-d-glucose by fibroblast

77 nificantly enhanced the cytotoxic effects of 2-deoxy-D-glucose and caused increases in endpoints indi

78 in fed mice pre-treated with 500 mg/kg i.p. 2-deoxy-D-glucose and in hypoglycemic mice fasted for 30

79 In contrast, GH decreased uptake of 2-deoxy-d-glucose and levels of Glut1 protein.

80 We monitor environmentally (2-deoxy-D-glucose) and genetically (DeltaPFK2) perturbed

81 jury which employs inhibitors of glycolysis (2-deoxy-D-glucose) and oxidative phosphorylation (antimy

82 Analysis of 3-O-methylglucose, 2-deoxy-D-glucose, and D-glucose uptake in the presence

83 sitron emission tomography and [18F]2-fluoro-2-deoxy-D-glucose, and general intellectual functions, m

84 ls were continuously treated (24 hours) with 2-deoxy-D-glucose, and total glutathione content as well

85 mission tomography (PET) with 2-[18F]-fluoro-2-deoxy-D-glucose as a radiotracer.

86 died with dynamic PET imaging of [18F]fluoro-2-deoxy-D-glucose at two occasions with 24-hour interval

87 graphy after an injection of [(18)F]2-fluoro-2-deoxy-d-glucose before the OGTT, and the rate of gluco

88 formed dynamic [(15)O]H2O and [(18)F]-fluoro-2-deoxy-d-glucose brain positron emission tomography sca

89 PET with [18F]fluoro-2-deoxy-D-glucose can be used to image cellular metaboli

90 PET with [(18)F]fluoro-2-deoxy-D-glucose can be used to image cellular metaboli

91 treatment of human breast cancer cells with 2-deoxy-d-glucose causes metabolic oxidative stress that

92 se results suggest that either D-glucose and 2-deoxy-D-glucose compete with a common cocaine and kapp

93 of the purified protein showed quenching by 2-deoxy-D-glucose, D-mannose, D-glucose or D-galactose i

94 On the other hand, 2-deoxy-d-glucose decreased the LPS-induced iNOS gene ex

95 e a comparable reduction of ATP levels (with 2-deoxy-D-glucose) did not induce these changes.

96 en when glucose utilization was blocked with 2-deoxy-D-glucose during the later part of the hypoxic p

97 T could be strongly inhibited by glucose and 2-deoxy-d-glucose even though the latter was not a good

98 Inhibiting GCL activity during 2-deoxy-D-glucose exposure using l-buthionine-[S,R]-sulf

99 uman cancers can be imaged by 2-[18F]-fluoro-2-deoxy-D-glucose (FDG) and PET, there is little clinica

100 malignant tumors with 2-[fluorine-18]-fluoro-2-deoxy-D-glucose (FDG) as a tracer is a noninvasive dia

101 2-[18F]-Fluoro-2-deoxy-d-glucose (FDG) cell labeling also was evaluated

102 emission tomography (PET) with [18F]-fluoro-2-deoxy-D-glucose (FDG) for lymph node staging in patien

103 Uptake of 2-[18F]-2-deoxy-D-glucose (FDG) has been used as a marker of inc

104 and cerebral metabolism using [(18)F]fluoro-2-deoxy-d-glucose (FDG) in Alzheimer's disease (AD) pati

105 ts infused with the glucose analog, 2-fluoro-2-deoxy-D-glucose (FDG) in vivo.

106 [18F]fluoro-2-deoxy-D-glucose (FDG) is a glucose analogue radiopharm

107 PET with 18F-fluoro-2-deoxy-D-glucose (FDG) is currently the noninvasive gol

108 was applied to dynamic 2-[fluorine-18]fluoro-2-deoxy-D-glucose (FDG) positron emission tomographic (P

109 -attenuation-corrected 2-[fluorine-18]fluoro-2-deoxy-D-glucose (FDG) positron emission tomography (PE

110 Fluorine-18 2-fluoro-2-deoxy-D-glucose (FDG) positron emission tomography (PE

111 8F]fluorodopamine ([18F]FDA) and [18F]fluoro-2-deoxy-D-glucose (FDG) positron emission tomography (PE

112 (MRGlc) in brain with PET and 2-[18F]fluoro-2-deoxy-D-glucose (FDG) requires knowing the rate of upt

113 ficity, and clinical utility of 18F 2-fluoro-2-deoxy-D-glucose (FDG) total-body positron emission tom

114 Although 2[18F]fluoro-2-deoxy-d-glucose (FDG) uptake during positron emission

115 into the origin of the (18)fluorine-labeled 2-deoxy-D-glucose (FdG) uptake signals observed clinical

116 mography (PET/CT) scanner with [F-18]-fluoro-2-deoxy-D-glucose (FDG) was evaluated.

117 After 20 mCi of 2-[18F]fluoro-2-deoxy-D-glucose (FDG) were administered intravenously,

118 In this study, the utility of 2-[18F]fluoro-2-deoxy-D-glucose (FDG) whole-body PET was evaluated as

119 otential cost-effectiveness of [18F]2-fluoro-2-deoxy-D-glucose (FDG)-PET in the management of SPN.

120 the labeled glucose analogue 2[(18)F]fluoro-2-deoxy-D-glucose (FDG).

121 olysis by replacing glucose in the bath with 2-deoxy-D-glucose had no effect.

122 sitron emission tomography using [18F]fluoro-2-deoxy-D-glucose has been studied as a tool to help pre

123 lammation using PET imaging of [(18)F]fluoro-2-deoxy-D-glucose in a porcine experimental model of ear

124 nstrate promise for the use of topotecan and 2-deoxy-D-glucose in children.

125 ATP depletion (5 mm NaCN and 5 mm 2-deoxy-d-glucose in the absence of medium glucose) caus

126 For example, in our system, sodium azide and 2-deoxy-D-glucose increased the ratio of cellular AMP to

127 s are treated with the hexokinase inhibitor, 2-deoxy-d-glucose, indicating that a functional glycolyt

128 dative stress and sensitizes cancer cells to 2-deoxy-D-glucose-induced cytotoxicity.

129 sponses elicited by food deprivation (24 h), 2-deoxy-D-glucose-induced glucoprivation (500 mg/kg) or

130 A receptor antagonism in both sites to alter 2-deoxy-D-glucose-induced intake, mercaptoacetate-induce

131 -deoxy-d-glucose uptake equals K(i(app)) for 2-deoxy-d-glucose inhibition of 3-O-methylglucose uptake

132 2-Deoxy-D-glucose, inhibits glucose metabolism and has b

133 aphy (PET) with FDG-glucose (2-[(18)F]fluoro-2-deoxy-d-glucose) is already being used as a metabolic

134 A combination of 2-deoxy-D-glucose, mannoheptulose and 3-0-methyl-glucose

135 Furthermore, inhibition of 2-deoxy-D-glucose-mediated induction of GCL activity wit

136 3 receptor (D3R) in the feeding responses to 2-deoxy-D-glucose, mercaptoacetate, and peripheral insul

137 strain had a significant effect on [F]fluoro-2-deoxy-D-glucose net uptake rate Ki in high-strain lipo

138 H or RVLM was elicited by microinjections of 2-deoxy-D-glucose or 5-thio-D-glucose in anesthetized, e

139 atments of B6.Sle1Sle2.Sle3 mice with either 2-deoxy-D-glucose or metformin were sufficient to preven

140 isease patients had cerebral 2-[(18)F]fluoro-2-deoxy-D-glucose PET ((18)FDG-PET), the results of whic

141 ncurrent EEG sleep studies and [(18)F]fluoro-2-deoxy-D-glucose PET scans during waking and NREM sleep

142 2-Fluoro-2-deoxy-D-glucose/PET studies in which glioma glucose me

143 creasing the rate of intracellular [F]fluoro-2-deoxy-D-glucose phosphorylation.

144 ognized and is exploited with (18)F-2-fluoro-2-deoxy-d-glucose positron emission tomography ((18)F-FD

145 2-[(18)F]Fluoro-2-deoxy-d-glucose positron emission tomography ([(18)F]F

146 e of this study was to compare 2-[18F]fluoro-2-deoxy-D-glucose positron emission tomography (FDG-PET)

147 the prognostic role of interim [18F]-fluoro-2-deoxy-D-glucose positron emission tomography (FDG-PET)

148 bolism, a phenomenon used in 2-[(18)F]fluoro-2-deoxy-D-glucose positron emission tomography imaging o

149 obese normal subjects with [(18)F]-2-fluoro-2-deoxy-D-glucose positron emission tomography imaging.

150 ecent developments in the use of [18F]fluoro-2-deoxy-D-glucose positron emission tomography in the cl

151 The utility of 2-[fluorine-18]-fluoro-2-deoxy-D-glucose positron emission tomography integrate

152 of autoimmune pancreatitis (6) 2-(18F)-Fluro-2-deoxy-D-glucose positron emission tomography might be

153 [18F]fluoro-2-deoxy-D-glucose positron emission tomography should no

154 [18F]fluoro-2-deoxy-D-glucose positron emission tomography should no

155 We used 2-[18F]-2-deoxy-D-glucose positron emission tomography to examin

156 [18F]fluoro-2-deoxy-D-glucose positron emission tomography will like

157 The 2-[(18)F]-fluoro-2-deoxy-D-glucose-positron emission tomography (FDG-PET)

158 identified by FDG-PET-CT (2-[(1)(8)F]fluoro-2-deoxy-D-glucose-positron emission tomography combined

159 cal, neuropsychological, and 2-[(18)F]fluoro-2-deoxy-d-glucose-positron emission tomography examinati

160 ars ago and currently exploited for 2-fluoro-2-deoxy-D-glucose-positron emission tomography imaging i

161 Early restaging fluoro-2-deoxy-D-glucose-positron emission tomography scans app

162 apted therapy on the basis of interim fluoro-2-deoxy-D-glucose-positron emission tomography scans hav

163 (ATGU) glucose uptake with [(18) F]2-fluoro-2-deoxy-D-glucose/positron emission tomography, lipolysi

164 objective of this MRI-guided 2-[(18)F]fluoro-2-deoxy-d-glucose/positron-emission tomography (FDG/PET)

165 furan product was formed, whereas the use of 2-deoxy-d-glucose resulted in reduced chemo- and stereos

166 of the response of yeast relative fitness to 2-deoxy-D-glucose reveals that control is distributed be

167 on emission tomography with [(18)F]-2-fluoro-2-deoxy-D-glucose scan in addition to noncontrast comput

168 of mechanical ventilation, dynamic [F]fluoro-2-deoxy-D-glucose scans were acquired to quantify metabo

169 ionine sulfoximine or energy depletion using 2-deoxy-D-glucose/sodium azide restored flutamide accumu

170 Thus, our findings are in accord with 2-Deoxy-D-glucose studies performed in V1 of macaques an

171 itron emission tomography and [18F]-2-fluoro-2-deoxy-D-glucose to determine cerebral metabolism.

172 We demonstrate defects in insulin action on 2-deoxy-D-glucose transport (SHRSP 3.3 +/- 1.5 vs. 21.0

173 during both AICAR and insulin infusion; [3H]2-deoxy-D-glucose transport activity increased to a simi

174 AICAR stimulated 2-deoxy-D-glucose transport twofold and reduced insulin-

175 hotoirradiated cells even in glucose-free or 2-deoxy-D-glucose-treated conditions.

176 in glucose-free medium or in the presence of 2-deoxy-D-glucose upon CCCP treatment.

177 2 to alanine (Q282A) doubled the Km(app) for 2-deoxy-d-glucose uptake and eliminated cis-allostery (s

178 l state, Q209L-Galphaq expression stimulated 2-deoxy-D-glucose uptake and GLUT4 translocation to 70%

179 A 2-deoxy-d-glucose uptake assay indicates that depletion

180 In soft tissue sarcomas, [18F]fluoro-2-deoxy-D-glucose uptake correlates with histologic grad

181 transport in human red cells, K(m(app)) for 2-deoxy-d-glucose uptake equals K(i(app)) for 2-deoxy-d-

182 reased the potency of insulin in stimulating 2-deoxy-D-glucose uptake in 3T3-L1 adipocytes, with a de

183 , we demonstrate that increased [18F]-fluoro-2-deoxy-D-glucose uptake in the right dorsolateral prefr

184 Reduction in [18F]fluoro-2-deoxy-D-glucose uptake is an early predictor of histol

185 Tidal strain enhances local [F]fluoro-2-deoxy-D-glucose uptake primarily by increasing the rat

186 [18F]fluoro-2-deoxy-D-glucose uptake rate was computed for the total

187 [(18)F]fluoro-2-deoxy-D-glucose uptake rate was computed for the whole

188 When 2-deoxy-D-glucose uptake was measured in these cells, th

189 Overload-induced [(3)H]-2-deoxy-d-glucose uptake was not inhibited by d-fructose

190 er 5 days, muscle weights and ex vivo [(3)H]-2-deoxy-d-glucose uptake were assessed.

191 ll effects were observed on IGF-1-stimulated 2-deoxy-D-glucose uptake.

192 nt or tidal hyperinflation had [(18)F]fluoro-2-deoxy-D-glucose uptakes similar to controls.

193 termediate gravitational zones [(18)F]fluoro-2-deoxy-D-glucose uptakes were higher in ventilator-indu

194 in oocytes were lower than maximal rates for 2-deoxy-d-glucose (Vmax of 224 and 32 pmol/min/oocyte fo

195 Injection of 2-deoxy-D-glucose was found to increase hemolymph glucos

196 ission tomography (PET) with [(18)F]2-fluoro-2-deoxy-D-glucose was used to measure changes in regiona

197 of radiolabelled D-glucose, D-galactose and 2-deoxy-D-glucose were restored, consistent with the exp

198 llular metabolism, and a treatment combining 2-deoxy-D-glucose, which inhibits glucose metabolism, an

199 reating infected cells with sodium azide and 2-deoxy-D-glucose, which we show rapidly and reversibly

200 riphosphate], is abolished by ATP depletion (2 deoxy-D-glucose with oligomycin or perfusion of apyras

201 s muscles were incubated ex vivo with [(3)H]-2-deoxy-d-glucose, with or without insulin or AICAR, bef